Education
About Us
Working with TipRanks
Follow Us
Novonesis (NVZMY)
OTHER OTC:NVZMY
NVZMY Stock Chart & Stats
$63.41
-$0.61(-1.09%)
At close: 4:00 PM EST
$63.41
-$0.61(-1.09%)
Day’s Range― - ―
52-Week Range$54.86 - $75.69
Previous CloseN/A
Volume8.66K
Average Volume (3M)1.56K
Market Cap
$25.71B
Enterprise Value$21.67B
Total Cash (Recent Filing)$295.60M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)287.4
Beta0.22
Next Earnings
May 05, 2026EPS Estimate
0.9Next Dividend Ex-DateN/A
Dividend Yield1.51%
Share Statistics
EPS (TTM)0.53
Shares Outstanding414,555,050
10 Day Avg. Volume2,114
30 Day Avg. Volume1,559
Financial Highlights & Ratios
PEG Ratio0.35
Price to Book (P/B)15.45
Price to Sales (P/S)40.34
P/FCF Ratio223.41
Enterprise Value/Market Cap0.84
Enterprise Value/Revenue5.21
Enterprise Value/Gross Profit9.67
Enterprise Value/Ebitda4.34
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.37
Revenue Forecast (FY)$5.21B
Bulls Say, Bears Say
Bulls Say
R&D And Product PipelineLarge, well-funded R&D program and strong IP protection create a durable product pipeline. High recent launch contribution (25% of sales) and AI-accelerated discovery shorten time-to-market, supporting sustainable organic growth, pricing power and differentiation over the medium term.
High And Expanding MarginsSustained high gross and EBITDA margins indicate structural cost advantage and pricing power across core businesses. Management guidance keeps margins elevated despite headwinds, implying durable operating leverage that can fund reinvestment, dividends and M&A without eroding profitability.
Strong Balance Sheet And Cash GenerationVery low reported debt and sizable equity cushion, combined with multi-hundred-million euro free cash flow in 2025, provide durable financial flexibility. This supports capex, integration spending, dividends and opportunistic M&A while lowering solvency and refinancing risks over the next several quarters.
Bears Say
Recent Revenue Decline And Profitability VolatilityMaterial revenue contraction and inconsistent margins across 2024–2025 reduce visibility into sustainable growth and earnings quality. Such structural variability makes forecasting returns harder, raises the bar for management to demonstrate durable recovery, and increases sensitivity to execution risk.
Higher CapEx And Restructuring CostsA step-up in capital intensity and restructuring raises medium-term cash needs and can depress free cash flow and ROIC while investments ramp. If new capacity or ERP benefits take longer to realize, elevated capex and integration costs could constrain cash available for dividends or discretionary investments.
Currency Translation And Market ExitsMeaningful FX translation risk and recent country exits (reducing organic growth) create persistent top-line volatility. Translation losses and a smaller addressable footprint can structurally lower reported growth and make operational performance more dependent on favorable currency moves or re-expansion execution.
Novonesis News
NVZMY FAQ
What was Novonesis’s price range in the past 12 months?
Novonesis lowest stock price was $54.86 and its highest was $75.69 in the past 12 months.
What is Novonesis’s market cap?
Novonesis’s market cap is $25.71B.
When is Novonesis’s upcoming earnings report date?
Novonesis’s upcoming earnings report date is May 05, 2026 which is in 55 days.
How were Novonesis’s earnings last quarter?
Novonesis released its earnings results on Feb 25, 2026. The company reported $0.531 earnings per share for the quarter, missing the consensus estimate of $0.791 by -$0.26.
Is Novonesis overvalued?
According to Wall Street analysts Novonesis’s price is currently Overvalued.
Does Novonesis pay dividends?
Novonesis pays a Semiannually dividend of $0.35 which represents an annual dividend yield of 1.51%. See more information on Novonesis dividends here
What is Novonesis’s EPS estimate?
Novonesis’s EPS estimate is 0.9.
How many shares outstanding does Novonesis have?
Novonesis has 414,555,050 shares outstanding.
What happened to Novonesis’s price movement after its last earnings report?
Novonesis reported an EPS of $0.531 in its last earnings report, missing expectations of $0.791. Following the earnings report the stock price went down -4.191%.
Which hedge fund is a major shareholder of Novonesis?
Currently, no hedge funds are holding shares in NVZMY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Novonesis Stock Smart Score
Company Description
Novonesis
Novonesis (NVZMY) is a technology-driven company specializing in innovative solutions for the healthcare and life sciences sectors. The company focuses on developing advanced biotechnology products and services aimed at improving patient outcomes and enhancing operational efficiencies within medical institutions. Novonesis is known for its cutting-edge research and development in drug delivery systems, diagnostic tools, and personalized medicine, positioning itself as a leader in the biopharmaceutical landscape.
NVZMY Company Deck
NVZMY Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a predominantly positive operational and financial story: solid organic growth (7% FY), strong margins (adjusted EBITDA 37.1%), excellent cash generation and EPS growth, successful M&A integration and a powerful innovation engine with large R&D and IP backing. Balanced against these positives are meaningful but manageable headwinds — chiefly currency impacts, effects from exiting certain countries, one-off integration and restructuring costs, timing variability in Agriculture/Tech, and a temporary step-up in CapEx. Management provided a constructive 2026 outlook (organic growth 5%–7%, EBITDA margin 37%–38%) that already incorporates the noted risks. On balance, highlights materially outweigh the lowlights.View all NVZMY earnings summariesNVZMY Revenue Breakdown
28.53% Household Care
24.83% Bioenergy
22.07% Food, Beverages & Human Health
12.82% Grain & Tech Processing
11.75% Agriculture & Animal Health
Technical Analysis
International Flavors & Fragrances
―
LyondellBasell
―
PPG Industries
―
RPM International
―
DuPont de Nemours
―
Ownership Overview
―
Insiders
<0.01% Mutual Funds
<0.01% Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---